| Morris H Smith, MD | |
|
1210 Nw 16th St, Fruitland, ID 83619-2202 | |
| (208) 452-8600 | |
| (208) 452-8601 |
| Full Name | Morris H Smith |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 60 Years |
| Location | 1210 Nw 16th St, Fruitland, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487611877 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD14123 (Oregon) | Secondary |
| 207R00000X | Internal Medicine | M3689 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Horizon Home Health | Meridian, ID | Home health agency |
| Encompass Health Home Health Of Western Idaho | Fruitland, ID | Home health agency |
| Signature Healthcare At Home | Nampa, ID | Home health agency |
| Saint Alphonsus Medical Center - Ontario, Inc | Ontario, OR | Hospital |
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Pioneer Nursing Home | Vale, OR | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Family Health Care Inc | 0547169591 | 36 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
"Arizona's hospital industry has decided not to push for an income tax increase on the state's wealthy to help the Arizona Health Care Cost Containment System," the Medicaid program in the state.
Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Bioengineers at Rice University and the University of Texas Medical Branch (UTMB) at Galveston have developed a simple, highly sensitive and efficient test for the diarrheal disease cryptosporidiosis that could have great impact on global health.
› Verified 2 days ago
| Entity Name | Valley Family Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295415032 PECOS PAC ID: 0547169591 Enrollment ID: O20040305000532 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
"Arizona's hospital industry has decided not to push for an income tax increase on the state's wealthy to help the Arizona Health Care Cost Containment System," the Medicaid program in the state.
Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Bioengineers at Rice University and the University of Texas Medical Branch (UTMB) at Galveston have developed a simple, highly sensitive and efficient test for the diarrheal disease cryptosporidiosis that could have great impact on global health.
› Verified 2 days ago
| Entity Name | Apogee Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558302174 PECOS PAC ID: 8820980188 Enrollment ID: O20040330000185 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
"Arizona's hospital industry has decided not to push for an income tax increase on the state's wealthy to help the Arizona Health Care Cost Containment System," the Medicaid program in the state.
Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Bioengineers at Rice University and the University of Texas Medical Branch (UTMB) at Galveston have developed a simple, highly sensitive and efficient test for the diarrheal disease cryptosporidiosis that could have great impact on global health.
› Verified 2 days ago
| Entity Name | Saint Alphonsus Medical Center- Ontario Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093034159 PECOS PAC ID: 1456488899 Enrollment ID: O20100713000593 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
"Arizona's hospital industry has decided not to push for an income tax increase on the state's wealthy to help the Arizona Health Care Cost Containment System," the Medicaid program in the state.
Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Bioengineers at Rice University and the University of Texas Medical Branch (UTMB) at Galveston have developed a simple, highly sensitive and efficient test for the diarrheal disease cryptosporidiosis that could have great impact on global health.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Morris H Smith, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: (208) 381-2222 | Morris H Smith, MD 1210 Nw 16th St, Fruitland, ID 83619-2202 Ph: (208) 452-8600 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
"Arizona's hospital industry has decided not to push for an income tax increase on the state's wealthy to help the Arizona Health Care Cost Containment System," the Medicaid program in the state.
Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Bioengineers at Rice University and the University of Texas Medical Branch (UTMB) at Galveston have developed a simple, highly sensitive and efficient test for the diarrheal disease cryptosporidiosis that could have great impact on global health.
› Verified 2 days ago
Dr. Isaac L Elam, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1210 Nw 16th St, Fruitland, ID 83619 Phone: 208-452-8600 | |
Dr. Mark David Christenson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 Nw 16th St Ste 102, Fruitland, ID 83619 Phone: 208-452-8015 Fax: 208-452-8055 |